6,7,4'-Trihydroxyflavanone 具有多种药理活性，包括抗风湿、抗缺血、抗炎、抗破骨细胞和对 METH 诱导的 T 细胞失活的保护作用。 6,7,4'-三羟基黄烷酮可用于研究治疗患有神经退行性疾病的 METH 成瘾者。

6,7,4'-Trihydroxyflavanone possesses various pharmacological activities, including anti-rheumatic, anti-ischemic, anti-inflammatory, anti-osteoclastogenic, and protective effects against METH-induced deactivation of T cells. 6,7,4'-Trihydroxyflavanone can be used for studies about the treatment of METH-addicts suffering from neurodegenerative diseases.

6,7,4'-Trihydroxyflavanone (40 μM) did not lead to cytotoxicity, but attenuated METH-induced neurotoxicity by modulating the expression of apoptosis-related proteins, METH-induced oxidative stress, and PI3K/Akt/mTOR phosphorylation in METH-exposed SH-SY5y cells. 6,7,4'-Trihydroxyflavanone induced Nrf2 nuclear translocation and HO-1 expression. The induction of HO-1 by 6,7,4'-Trihydroxyflavanone attenuates METH-induced neurotoxicity[1].

6,7,4'-Trihydroxyflavanone (20 and 50 mg/kg; orally) alleviates dextran sulfate sodium (DSS)-induced colitis by modulating the activity of T cells and colon cells in vivo including a reduction in body weight, shrinkage of the colon, and enhanced expression of pro-inflammatory cytokines in the colon and mesenteric lymph nodes[2].

189689-31-4

C15H12O5

272.25

6,7,4'-Trihydroxyflavanone

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years